China NMPA Drug Inspection - Pingliang Yongcheng Pharmaceutical Co., Ltd. - Bupleurum

On July 21, 2017, the Ningxia Food and Drug Administration (now part of the National Medical Products Administration - NMPA) issued an announcement correcting previously published drug quality sampling inspection information from May 31, 2017. This correction pertained to the '2017 Ningxia Drug Quality Sampling Inspection,' which encompassed a wide range of pharmaceutical products, including both Western medicines and Traditional Chinese Medicine (TCM) pieces. The inspection involved numerous companies, with samples sourced from various pharmacies, health centers, and hospitals across Ningxia. A comprehensive list of 174 drug products was detailed. Crucially, the document reported that all 174 sampled drug products were found to be compliant with the applicable regulatory frameworks, primarily the Chinese Pharmacopoeia (various editions and parts), Ministry of Health Drug Standards, and National Drug Standards. As a result, no main violations or quality issues were identified for any of the listed manufacturers or products during this sampling inspection. The required action was an administrative correction of the initial announcement's data, ensuring accuracy in public reporting, rather than addressing product non-compliance.